Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
INMD 
InMode Ltd (INMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: INMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.25
1 Year Target Price $16.25
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.36% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 937.39M USD | Price to earnings Ratio 6.23 | 1Y Target Price 16.25 |
Price to earnings Ratio 6.23 | 1Y Target Price 16.25 | ||
Volume (30-day avg) 7 | Beta 2.01 | 52 Weeks Range 13.14 - 19.85 | Updated Date 09/14/2025 |
52 Weeks Range 13.14 - 19.85 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 44.5% | Operating Margin (TTM) 23.93% |
Management Effectiveness
Return on Assets (TTM) 9.14% | Return on Equity (TTM) 25.91% |
Valuation
Trailing PE 6.23 | Forward PE 8.34 | Enterprise Value 432811724 | Price to Sales(TTM) 2.33 |
Enterprise Value 432811724 | Price to Sales(TTM) 2.33 | ||
Enterprise Value to Revenue 1.08 | Enterprise Value to EBITDA 3.75 | Shares Outstanding 63209200 | Shares Floating 53530168 |
Shares Outstanding 63209200 | Shares Floating 53530168 | ||
Percent Insiders 15.35 | Percent Institutions 59.25 |
Upturn AI SWOT
InMode Ltd
Company Overview
History and Background
InMode Ltd. was founded in 2008. The company designs, develops, manufactures, and markets innovative energy-based medical aesthetic products. It has expanded its product portfolio through internal development and strategic acquisitions, establishing itself as a key player in the aesthetic medical device market.
Core Business Areas
- Surgical Technologies: Develops and markets minimally invasive surgical aesthetic solutions using radio-frequency (RF) energy.
- Aesthetic Medical Technologies: Offers non-invasive and minimally invasive aesthetic treatment platforms for various applications like skin tightening, body contouring, and hair removal.
Leadership and Structure
The company is led by CEO and Chairman Moshe Mizrahy. The organizational structure includes departments for R&D, sales & marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- BodyTite: Minimally invasive body contouring and skin tightening device using RFAL (Radio-Frequency Assisted Lipolysis). Competitors include Cutera (CUte), Allergan Aesthetics (ABBV).
- Morpheus8: Fractional RF microneedling for skin resurfacing and tightening. Competitors include Candela (owned by Apax Partners), Lutronic.
- Evolve: Hands-free platform for body contouring and muscle toning. Competitors include BTL Aesthetics, Venus Concept (VERO).
Market Dynamics
Industry Overview
The aesthetic medical device market is experiencing growth driven by increasing demand for minimally invasive procedures. Technological advancements and rising disposable incomes are key growth factors.
Positioning
InMode is positioned as a technology leader in the aesthetic medical device market, offering innovative energy-based solutions. Their competitive advantage lies in their proprietary RF technologies and minimally invasive approach.
Total Addressable Market (TAM)
The estimated TAM for the global medical aesthetics market is approximately $15 billion. InMode Ltd. is positioning itself to capture a significant share of this growing market with its diverse product portfolio.
Upturn SWOT Analysis
Strengths
- Innovative technology
- Strong brand recognition
- Global presence
- High profit margins
- Recurring revenue model from consumables
Weaknesses
- Reliance on a few key products
- Competition from larger players
- Regulatory risks
- Dependence on physician adoption
Opportunities
- Expanding into new markets
- Developing new applications for existing technologies
- Strategic acquisitions
- Increasing consumer awareness
Threats
- Increased competition
- Technological obsolescence
- Economic downturns
- Changes in regulations
Competitors and Market Share
Key Competitors
- ALGN
- ZTS
- ABBV
- CUte
- LNC
Competitive Landscape
InMode's competitive advantage lies in its innovative technology and minimally invasive approach. However, it faces competition from larger, more established players with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: InMode has demonstrated strong revenue growth over the past several years, driven by product adoption and market expansion.
Future Projections: Analysts project continued growth for InMode, driven by increasing demand for aesthetic procedures and the introduction of new products.
Recent Initiatives: Recent initiatives include expanding into new markets, investing in R&D, and launching new products.
Summary
InMode is a strong company with innovative technology and high profit margins. It faces competition from larger players and depends on physician adoption. Continued growth depends on market expansion and new product development, while it must watch regulatory changes and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMode Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-08-08 | Co-Founder, CEO & Director Mr. Moshe Mizrahy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 599 | Website https://www.inmodemd.com |
Full time employees 599 | Website https://www.inmodemd.com | ||
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.